Endologix To Participate In Lazard Capital Markets Corporate Access Day

IRVINE, Calif., Sept. 12, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to participate in the Lazard Capital Markets Corporate Access Day investor conference in Boston. This conference will allow institutional investors to meet with Endologix but does not include a formal presentation.

                         Event:             Lazard Capital Markets Corporate Access Day                    

                        Date:              Tuesday, September 18, 2012

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
CONTACT: COMPANY CONTACT:         Endologix, Inc.         John McDermott, CEO         (949) 595-7200         www.endologix.com                  INVESTOR CONTACTS:         The Ruth Group         Nick Laudico (646) 536-7030         Zack Kubow (646) 536-7020

If you liked this article you might like

Endologix Poised for a Potentially Volatile Breakout

5 Stocks Trending Close to Major Breakouts

5 Stocks Set for Explosive Breakouts

These 5 Stocks Under $10 Could Make You a Lot of Money

Week in Review: Trump Rally Fizzles but Stocks End 2016 With Big Gains